Skip to main
LLY

Eli Lilly (LLY) Stock Forecast & Price Target

Eli Lilly (LLY) Analyst Ratings

Based on 20 analyst ratings
Buy
Strong Buy 40%
Buy 50%
Hold 5%
Sell 5%
Strong Sell 0%

Bulls say

Eli Lilly is a leader in the biopharmaceutical industry with a diverse portfolio of drugs focused on key therapeutic areas including neuroscience, cardiometabolic, cancer, and immunology. The company's strong performance and portfolio diversification suggest continued success, particularly in the oncology and obesity spaces, where the company's products have shown strong growth. Management's commitment to research and development gives confidence in future pipeline developments and the potential for even more growth. Despite some challenges in the retail market in which it operates, Eli Lilly has demonstrated resilience and is positioned for further success in the industry.

Bears say

Eli Lilly is facing multiple downside risks as potential pricing and rebate pressure, slower Rx trajectory of tirzepatide, and a worse-than-expected launch of Forglipron could all impact the company's financial performance. Additionally, the company's pipeline products may not perform as well as expected, and highest costs may decrease earnings. Despite expecting a guidance raise, the analyst also notes that it may not be as significant as previous increases, and points to Medicare expansion and global opportunities as potential positives. However, with a 30x P/E multiple, this outlook reflects a negative sentiment towards the company's prospects.

Eli Lilly (LLY) has been analyzed by 20 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 50% recommend Buy, 5% suggest Holding, 5% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Eli Lilly and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Eli Lilly (LLY) Forecast

Analysts have given Eli Lilly (LLY) a Buy based on their latest research and market trends.

According to 20 analysts, Eli Lilly (LLY) has a Buy consensus rating as of Aug 2, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1,296.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1,296.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Eli Lilly (LLY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.